(Q38212717)

31 August 2017

title

The clinical development of MEK inhibitors (English)

1 reference

31 August 2017

Yujie Zhao

1

1 reference

31 August 2017

Alex A Adjei

series ordinal

2

1 reference

31 August 2017

language of work or name

English

0 references

publication date

20 May 2014

1 reference

Nature Reviews Clinical Oncology

31 August 2017

published in

1 reference

31 August 2017

volume

11

1 reference

31 August 2017

issue

7

1 reference

31 August 2017

page(s)

385-400

1 reference

Mitogen-activated protein kinase pathways

31 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Mammalian MAP kinase signalling cascades

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Phosphatidylinositol 3-kinase requirement in activation of the ras/C-raf-1/MEK/ERK and p70(s6k) signaling cascade by the insulinomimetic agent vanadyl sulfate

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Requirement of Ras-GTP-Raf Complexes for Activation of Raf-1 by Protein Kinase C

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Raf-1 protein kinase is required for growth of induced NIH/3T3 cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

A full-length 3D structure for MAPK/ERK kinase 2 (MEK2).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

MEK inhibitors: a patent review 2008 - 2010.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

A comprehensive survey of Ras mutations in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

ERK1/2 MAP kinases: structure, function, and regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

The MEK/ERK cascade: from signaling specificity to diverse functions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Selective requirement for MAP kinase activation in thymocyte differentiation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Sequential protein kinase reactions controlling cell growth and differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Inhibition of ERK1/2 prevents neural and mesendodermal differentiation and promotes human embryonic stem cell self-renewal

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Differential regulation and properties of MAPKs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Signaling from Ras to Rac and beyond: not just a matter of GEFs

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

RAS Interaction with PI3K: More Than Just Another Effector Pathway

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Distinct requirements for Ras oncogenesis in human versus mouse cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Improved survival with MEK inhibition in BRAF-mutated melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Raf-1 physically interacts with Rb and regulates its function: a link between mitogenic signaling and cell cycle regulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Raf-1 sets the threshold of Fas sensitivity by modulating Rok-alpha signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Raf family kinases: old dogs have learned new tricks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Heterogeneous nuclear ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells by regulating A-Raf transcription

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Regulation and role of Raf-1/B-Raf heterodimerization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Regulation of Raf-1 by direct feedback phosphorylation.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Ocular toxicity of targeted therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Dropped head syndrome: report of three cases during treatment with a MEK inhibitor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

A phase I dose-finding, safety and tolerability study of AZD8330 in patients with advanced malignancies.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

The discovery of the benzhydroxamate MEK inhibitors CI-1040 and PD 0325901.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

PD0325901, a mitogen-activated protein kinase kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/K-mutated melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Phase II study of the mitogen-activated protein kinase 1/2 inhibitor selumetinib in patients with advanced hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

RET/PTC-induced dedifferentiation of thyroid cells is mediated through Y1062 signaling through SHC-RAS-MAP kinase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Novel Carboxamide-Based Allosteric MEK Inhibitors: Discovery and Optimization Efforts toward XL518 (GDC-0973)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

The role of signaling pathways in the development and treatment of hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

The European Academy of Cancer Sciences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

The safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of CH4987655 in healthy volunteers: target suppression using a biomarker.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of the MEK inhibitor RO4987655 (CH4987655) in patients with advanced solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Enhanced inhibition of ERK signaling by a novel allosteric MEK inhibitor, CH5126766, that suppresses feedback reactivation of RAF activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

TMEM16A alternative splicing coordination in breast cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2014.83

Role of RAS in the regulation of PI 3-kinase

31 March 2020

1 reference

12 December 2020

Signal transduction through MAP kinase cascades

1 reference

12 December 2020

BRAF and RAS mutations in human lung cancer and melanoma

1 reference

12 December 2020

New drugs in melanoma: it's a whole new world

1 reference

12 December 2020

10.1038/NRCLINONC.2014.83

Identifiers

DOI

1 reference

31 August 2017

1 reference